Genomics England, a UK government-owned genomic sequencing company, has joined forces with Swedish medical imaging and cybersecurity firm Sectra to “push the boundaries” of cancer research by linking up cancer images from NHS trusts data with genomics data and AI.
A cancer research initiative, launched late last month, will see diagnostic imaging data taken from patients across 30 National Health Service (NHS) trusts linked with whole genome sequencing data from Genomics England using technology developed by Sectra.
The NHS is responsible for diagnosing and treating the vast majority of people with cancer who live in the UK, and its database holds the medical records of around 65...
The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.
The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.
Moves are at last underway for a more specific focus on orphan and pediatric devices. They are a start; but experts are calling for more to support this sector.
Post-market surveillance regulations for medtech system users in Great Britain coming into force on 16 June will make new data requirements under new compliance deadlines.
Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.
A study from Babson Diagnostics published in the peer-reviewed Journal of Applied Laboratory Medicine showed that capillary blood sample volume issues can overcome historical challenges, such as poor quality, through a technique called assay miniaturization.
The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.
